Sapu Nano Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
- Written by: Viw Magazine
SAN DIEGO, US - Media OutReach Newswire - 9 July 2026 - Sapu Nano (US) LLC, a clinical-stage biotechnology company developing the proprietary Deciparticle™ nanomedicine platform, today announced that the independent Safety Review Committee (SRC) has completed its review of the initial safety cohort in the Company's ongoing SP-03-B101 Phase 1b clinical trial evaluating Sapu003, an investigational intravenous formulation of everolimus.
